Introduction
Nowadays, cancer is a leading cause of mortality. According to a recent survey, 8.2 million people die from cancer each year and 14.1 million new cases were diagnosed with cancer worldwide. 1 A majority of the cancer cases can ultimately develop metastases, which included lymph node metastases (LNM) and distant metastases (DM). The occurrence of metastasis was a critical indicator for survival, which indicated poor prognosis in most cancers. 2, 3 In addition, the treatment measures were also determined by whether there was metastasis or not. Until now, the precise mechanism on metastasis in cancer cells is still unclear. In recent years, molecular biomarkers, as a hotspot in cancer research, have raised a revolution in the prediction and treatment of cancer. [4] [5] [6] Until now, we still know nothing about the role of HOXB7 in predicting metastases of various cancers, although it may act as a common molecular marker for both LNM and DM.
HOX genes belong to an important component of superfamily of homeobox genes. A large family of transcriptional factors were encoded, and the expression of many downstream target genes was regulated by HOX genes. 7, 8 Human HOX genes can be divided into two classes. In class I, there were four paralogous clusters of HOX genes, and they were defined as HOXA, HOXB, HOXC, and HOXD, which were arranged in 2, 12, 17, and 7 chromosomes in turn. [9] [10] [11] Many studies have reported that HOX genes submit your manuscript | www.dovepress.com
Dovepress

2694
liu et al were frequently deregulated in cancers, which could widely make effects on cellular functions, including proliferation, differentiation, and apoptosis. [12] [13] [14] [15] HOX genes were also involved in tumor initiation and progression. 16, 17 HOXB7, as one of class I HOX genes, was found to participate in the process of various cancers, such as gastric cancer, breast cancer (BC), and pancreatic carcinoma. [18] [19] [20] Some studies revealed that HOXB7 played a crucial role in tumorigenesis and was closely related to the viability, invasion, and metastasis of tumor cells. 21, 22 A number of studies have demonstrated that the expression level of HOXB7 was upregulated in cancerous tissues and was associated with some clinical features, including LNM and DM. [23] [24] [25] Therefore, in this study, we collected relevant literatures and performed the meta-analysis. It aimed to explore the relationship between the HOXB7 expression and metastasis and further determine whether HOXB7 could be applied as a putative biomarker for indicating metastasis in cancer patients.
Methods
literatures' retrieval strategy
For obtaining potentially eligible studies, integrated online literature retrieval was performed against multiple databases, including PubMed, Springer, Google Scholar, China National Knowledge Infrastructure (CNKI), Chongqing VIP Information Network, and Wanfang. The deadline of retrieval period was up to December 1, 2015. The keywords for the search were as follows: "Homeobox B7", "HOXB7", "cancer", "carcinoma", and "neoplasm". In addition, other relevant articles were also obtained by manually viewing the reference list.
inclusion and exclusion criteria
Inclusion criteria for the articles were as follows: 1) the role of HOXB7 in the development of human cancer was investigated; 2) related clinicopathologic parameters were described; 3) the expression level of HOXB7 in primary cancerous tissue was measured; and 4) patients were grouped according to the expression level of HOXB7.
Exclusion criteria for the articles were as follows: 1) duplicate publications; 2) studies without valuable data; and 3) reviews, letters, case reports, and expert opinions.
Date extraction
The data and information from all eligible studies were independently extracted by two investigators (YX O and GP Z). The following data and information were collected from each study: author, publication year, country, race, cancer type, total number of patients, number of high HOXB7 expression group and low HOXB7 expression group, number of patients with LNM and DM in each group, and the criteria of high HOXB7 expression. If there were disagreements, a consensus was reached by a third investigator (CQ).
statistical methods
The present meta-analysis was conducted using RevMan5.3 software and Stata SE12.0. The heterogeneity among eligible studies was determined with the chi-square-based Q-test and I 2 statistics; a P-value for Q-test ,0.05 and I 2 -value .50% were considered severe heterogeneity. The random-effects model was applied in studies with a significant heterogeneity (P Q #0.05, I
2 $50%); otherwise, the fixed-effects model was adopted (P Q .0.05, I
2 ,50%). Potential publication bias was assessed with a funnel plot, and sensitivity analysis was also performed to ensure the reliability of results. The P-value ,0.05 was considered statistically significant.
Result
studies' characteristics
The process of literature retrieval is shown in detail in Figure 1 . A total of 14 studies were finally identified to be eligible according to the criteria for selection. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] A total of 1,532 patients were included in the current meta-analysis, and the mean sample size of patients was 109.4 (range: 35-280). Among the 14 studies, 12 were from the People's Republic of China, two were from Brazil, and one was from the USA. Eight different cancer types were evaluated in this meta-analysis, with two BC, three esophagus cancer, one gastric cancer, one lung cancer, two pancreatic cancer, two colorectal cancer, two oral cancer, and one malignant ovarian germ cell tumor. All cancerous specimens were well preserved before RNA extraction. The diagnoses of LNM and DM were all based on pathology.
There were two studies that reported on the association between the expression of HOXB7 mRNA and LNM, 23, 29 and the rest 12 articles have paid attention on the association of HOXB7 protein expression and metastases. Two detection methods (reverse transcription polymerase chain reaction and immunohistochemical staining) were applied to determine the expression levels of HOXB7 in cancerous tissues. The criteria of high HOXB7 expression in all included studies are shown in Table 1 . All studies were divided into two groups (high HOXB7 expression group and low HOXB7 expression group). For unifying the result for further analysis, positive expression of HOXB7 was regarded as high expression and negative expression of HOXB7 was classified into low expression group.
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hOXB7 as a molecular marker for metastasis in cancers association between hOXB7 expression level and lnM All 14 studies provided the number of patients with LNM based on different HOXB7 expression levels in a total of 1,532 patients. The fixed-effects model was adopted as there was limited heterogeneity across studies (I 2 =0%, P Q =0.59). The odds ratio (OR), expressed as high HOXB7 expression group versus low HOXB7 expression group, was 2.17 (95% CI: 1.74-2.71, P,0.00001; Figure 2 ). In the subgroup analysis, the result showed that there was a significant association between the expression level of HOXB7 mRNA and LNM (OR =2.22, 95% CI: 1.26-3.91, P=0.006). For the association between the expression level of HOXB7 protein and LNM, the OR, expressed as high HOXB7 protein expression group versus low HOXB7 protein expression group, was 2.16 (95% CI: 1.70-2.76, P,0.00001). From the analysis results, when the LNM incidence of cancers was compared between the two groups, we found that there was a significant difference in the LNM incidence between the high and low expression groups. This result demonstrated that cancer patients determined with high HOXB7 expression (including mRNA and protein) in cancerous tissues were more prone to developing LNM.
association between hOXB7 expression level and DM
Five studies reported the number of patients with DM based on different HOXB7 protein expression levels in a total of 544 patients. There was no significant heterogeneity among the studies (I 2 =15%, P Q =0.32); thus, the fixed-effects model was adopted. Analysis showed a pooled OR =1.77 (95% CI: 1.09-2.88, P=0.02; Figure 3) . Compared with the low HOXB7 expression group, the DM rate was significantly increased in the high HOXB7 expression group. The result showed that patients with high HOXB7 protein expression level in tumor tissues may indicate an increased risk of developing DM.
In addition, sensitivity analysis and assessment of publication bias were not performed due to the relatively small heterogeneity across studies in distant metastasis and limited number of included studies.
Publication bias
For meta-analysis of the association between HOXB7 expression level and LNM, the funnel plot was slightly asymmetrical (Figure 4) , and then, the trim and fill method was applied to test for publication bias. The results showed that there was no significant publication bias across these studies. Table 1 The basic information and data of all included studies in the meta-analysis For meta-analysis of the association between HOXB7 expression level and LNM, sensitivity analysis was performed by deleting each study in turn from the pooled analysis. It aimed to test the influence of the removed data set on the overall ORs. The result was not significantly influenced by the exclusion of each study, suggesting that the result of synthetic analysis was robust.
Discussion
As we all know, cancer is a severe threat to human health, and there are millions of people who die from cancer every year.
The LNM is the most common metastasis pathway in most cancers, and distant metastasis often occurs in the later stages of cancer. LNM and DM are positively significant for diagnosis in tumor-node-metastasis staging and treatment for cancer patients, as well as are important indicators for predicting prognosis. Thereby, further discovery of new molecular markers to predict metastasis for cancer is still essential and full of clinical significance. A growing number of researches have showed that the expression of HOXB7 was higher in cancerous tissues compared with paired noncancerous tissues. There were associations between HOXB7 expression and certain clinical characteristics of cancer patients. The patients with high expression levels of HOXB7 had an increased risk of metastasis as well as a poor overall survival. [26] [27] [28] Furthermore, the overexpression of HOXB7 was closely related to the aggressive behavior of tumor cells. However, the exact mechanism of how HOXB7 makes effects on promoting tumor cell invasion and metastasis has not been clear and is still in research stage. Wu et al 37 found that tumor invasion in BC could be promoted by HOXB7 through Ras/Rho pathway activation after upregulating basic fibroblast growth factor (bFGF), which was a known transcriptional target of HOXB7. In the malignant melanoma, it has demonstrated that miR-196a was a central regulator of HOXB7 expression, which played an important role in melanoma progression. 38 Recently, a study by Liu et al 39 showed that the migration and invasion of BC cells may be increased by overexpression of HOXB7, and this result could be reversed by knockdown of transforming growth factor (TGF)β2 or pharmacologic inhibition of TGFβ signaling. It suggested that HOXB7 may make effects on promoting tumor malignant progression through the activation of TGFβ signaling pathway. [42] [43] [44] HOXB7 was also found to promote the migration and metastasis in lung adenocarcinoma through activation of the TGFβ/SMAD3 signaling. 40 Chile et al 41 reported that HOXB7 was also involved in cell proliferation and viability. Cell cycle arrest and apoptosis could be induced by the knockdown of HOXB7 in pancreatic ductal adenocarcinomas, while decreased protein level could significantly lead to the increased apoptosis rate. HOXB7 may be a promising target for future cancer therapies.
Conclusion
This meta-analysis has explored the relation between HOXB7 expression levels with LNM and DM for carcinoma. From the results of this current meta-analysis, we found that the occurrence probability of LNM and DM was higher in cancer patients with high HOXB7 expression, comparing with that of those with low HOXB7 expression. Nevertheless, we also found that there were some limitations in this meta-analysis. Firstly, the included number of cancer patients has been still relatively small, hence larger and better design studies would be necessary to confirm the obtained results. Besides, most patients included in this meta-analysis have been Asian, the patients of other races accounted for a small percentage. Additionally, potential publication bias may exist, although no significant publication bias was observed based on trim and fill method and the sensitivity analysis have also showed the results were robust. Furthermore, the criterion of high HOXB7 expression was varied in these studies. Therefore, more larger size, multicenter, and higher quality studies are needed for further research, based on a unified criterion for classifying HOXB7 expression groups.
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